Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Calidi Biotherapeutics, Inc.CLDI · Entity 8408 | Chief Executive Officer | August 17, 2026 | August 19, 2026 |
| Molecular Templates, Inc.MTEM · Entity 85987 | Director · See remarks | January 23, 2024 | January 25, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Calidi Biotherapeutics, Inc.
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2036-08-17 | Direct | 32,000 |
Reported balance
After 2026-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-17 · Grant · Acquired 32,000 · Balance 32,000 F1: Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on August 17, 2026 (the "Grant Date"), the Reporting Person was granted 32,000 incentive stock options (the "Options") at an exercise price of $1.36, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 08/17/2026, and the remaining 75% of the options will vest in 1/36th installments on a monthly basis, subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. F2: Does not include the incentive stock options previously granted to the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on August 17, 2026 (the "Grant Date"), the Reporting Person was granted 32,000 incentive stock options (the "Options") at an exercise price of $1.36, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 08/17/2026, and the remaining 75% of the options will vest in 1/36th installments on a monthly basis, subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.
F2: Does not include the incentive stock options previously granted to the Reporting Person.
Molecular Templates, Inc.
Report date January 23, 2024 · Filed January 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.55 · Expires 2034-01-22 | Direct | 23,333 |
Reported balance
After 2024-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-23 · Grant · Acquired 23,333 · Balance 23,333 F1: The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on August 11, 2023. F2: 25% of the total number of shares subject to the option shall vest on January 23, 2025, and the remaining 75% shall vest in thirty-six (36) equal monthly installments, subject to the reporting person's continued service through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on August 11, 2023.
F2: 25% of the total number of shares subject to the option shall vest on January 23, 2025, and the remaining 75% shall vest in thirty-six (36) equal monthly installments, subject to the reporting person's continued service through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 19, 2026 23:00 UTC | Calidi Biotherapeutics, Inc. CLDI · Entity 8408 | GrantStock Options (right to buy) · Derivative | 32,000 | Not disclosed Strike: $1.36 | Not disclosed |
DisclosureSEC source: 0001493152-26-039287 · ownership.xml · derivative · entry 1 Poma Eric E · CIK 0001339484 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common stock · 32,000 shares Expires 2036-08-17 F1 · price: Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on August 17, 2026 (the "Grant Date"), the Reporting Person was granted 32,000 incentive stock options (the "Options") at an exercise price of $1.36, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 08/17/2026, and the remaining 75% of the options will vest in 1/36th installments on a monthly basis, subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. F2 · balance_after: Does not include the incentive stock options previously granted to the Reporting Person. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 23:56 UTC | Calidi Biotherapeutics, Inc. CLDI · Entity 8408 | GrantStock Options (right to buy) · Derivative | 10,000 | Not disclosed Strike: $1.58 | Not disclosed |
DisclosureSEC source: 0001641172-25-026782 · ownership.xml · derivative · entry 1 Poma Eric E · CIK 0001339484 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common stock · 10,000 shares Expires 2035-09-03 F1 · price: Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on September 3, 2025 (the "Grant Date"), the Reporting Person was granted 10,000 incentive stock options (the "Options") at an exercise price of $1.58, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 9/03/2025, and the remaining 75% of the options will vest in 1/36th installments on the last day of each monthly period subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person. Read SEC document |
| August 21, 2025 Filed Aug 26, 2025 00:47 UTC | Calidi Biotherapeutics, Inc. CLDI · Entity 8408 | PurchaseWarrant (right to buy) · Derivative | 25,000 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0001641172-25-025447 · ownership.xml · derivative · entry 2 Poma Eric E · CIK 0001339484 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common stock · 25,000 shares Expires 2030-08-21 F1 · kind: The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025. F2 · price: Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant. Read SEC document |
| August 21, 2025 Filed Aug 26, 2025 00:47 UTC | Calidi Biotherapeutics, Inc. CLDI · Entity 8408 | PurchaseCommon Stock | 25,000 | $2.00 | $50,000.00 |
DisclosureSEC source: 0001641172-25-025447 · ownership.xml · nonDerivative · entry 1 Poma Eric E · CIK 0001339484 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The common stock and warrants were acquired by the reporting person in a public offering conducted by the Issuer that was closed on August 21, 2025. F2 · price: Each common share was purchased with an accompanying warrant for a purchase price of $2.00 per share and accompanying warrant. Read SEC document |
| April 22, 2025 Filed Apr 25, 2025 10:05 UTC | Calidi Biotherapeutics, Inc. CLDI · Entity 8408 | GrantStock Option (right to buy) · Derivative | 726,412 | Not disclosed Strike: $0.47 | Not disclosed |
DisclosureSEC source: 0001641172-25-006070 · ownership.xml · derivative · entry 1 Poma Eric E · CIK 0001339484 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 726,412 Underlying: Common Stock · 726,412 shares Expires 2035-04-22 F1 · price: On April 22, 2025 (the "Grant Date"), the compensation committee and board of directors of Calidi Biotherapeutics, Inc. ("Issuer") approved an inducement grant to the Reporting Person of 726,412 stock options (the "Options"), pursuant to the exception under Section 711 NYSE American, at a per share exercise price of $0.4690, which is equal to the closing price of the Issuer's common stock on the Grant Date. F2 · price: 25% of the options will vest upon the one (1) year anniversary of 04/22/2025, and the remaining 75% of the options will vest in 1/36th installments on the last day of each monthly period subject to the Reporting Person's continued service to the Issuer. F1 · derivative.exercise_date: On April 22, 2025 (the "Grant Date"), the compensation committee and board of directors of Calidi Biotherapeutics, Inc. ("Issuer") approved an inducement grant to the Reporting Person of 726,412 stock options (the "Options"), pursuant to the exception under Section 711 NYSE American, at a per share exercise price of $0.4690, which is equal to the closing price of the Issuer's common stock on the Grant Date. F2 · derivative.underlying_shares: 25% of the options will vest upon the one (1) year anniversary of 04/22/2025, and the remaining 75% of the options will vest in 1/36th installments on the last day of each monthly period subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 17:32 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 23,333 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0000950170-24-007535 · ownership.xml · derivative · entry 1 Poma Eric E · CIK 0001339484 · Director · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,333 Underlying: Common Stock · 23,333 shares Expires 2034-01-22 F1 · derivative.exercise_price: The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on August 11, 2023. F2 · derivative.exercise_date: 25% of the total number of shares subject to the option shall vest on January 23, 2025, and the remaining 75% shall vest in thirty-six (36) equal monthly installments, subject to the reporting person's continued service through the applicable vesting dates. F1 · derivative.underlying_shares: The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on August 11, 2023. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 08:00 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0000899243-23-005365 · doc4.xml · derivative · entry 1 Poma Eric E · CIK 0001339484 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2033-02-14 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 15, 2024, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over the following 36 months. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 08:00 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | Exercise / conversionStock Option (right to buy) · Derivative | 27,325 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0000899243-22-015976 · doc4.xml · derivative · entry 4 Poma Eric E · CIK 0001339484 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,325 shares Expires 2022-07-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option, representing a right to purchase a total of 27,325 shares, became exercisable in equal monthly installments over a five-year period beginning on July 10, 2012. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 08:00 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | Exercise / conversionStock Option (right to buy) · Derivative | 6,831 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0000899243-22-015976 · doc4.xml · derivative · entry 3 Poma Eric E · CIK 0001339484 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,831 shares Expires 2022-07-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option, representing a right to purchase a total of 6,831 shares, became exercisable in equal monthly installments over a five-year period beginning on July 10, 2012. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 08:00 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | Exercise / conversionCommon Stock | 27,325 | $0.71 | $19,400.75 |
DisclosureSEC source: 0000899243-22-015976 · doc4.xml · nonDerivative · entry 2 Poma Eric E · CIK 0001339484 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 08:00 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | Exercise / conversionCommon Stock | 6,831 | $0.71 | $4,850.01 |
DisclosureSEC source: 0000899243-22-015976 · doc4.xml · nonDerivative · entry 1 Poma Eric E · CIK 0001339484 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 08:00 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0000899243-22-006729 · doc4.xml · derivative · entry 1 Poma Eric E · CIK 0001339484 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 15, 2023, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over the following 36 months. Read SEC document |
| July 06, 2021 Filed Jul 7, 2021 07:30 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | Exercise / conversionStock Option (right to buy) · Derivative | 3,563 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0000899243-21-027737 · doc4.xml · derivative · entry 2 Poma Eric E · CIK 0001339484 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,563 shares Expires 2021-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares underlying this option are fully vested. Read SEC document |
| July 06, 2021 Filed Jul 7, 2021 07:30 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | Exercise / conversionCommon Stock | 3,563 | $0.71 | $2,529.73 |
DisclosureSEC source: 0000899243-21-027737 · doc4.xml · nonDerivative · entry 1 Poma Eric E · CIK 0001339484 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 16:55 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $14.05 | $0.00 |
DisclosureSEC source: 0000899243-21-006902 · doc4.xml · derivative · entry 1 Poma Eric E · CIK 0001339484 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-02-15 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 15, 2022, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over the following 36 months. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 21:59 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 312,500 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0000899243-20-004988 · doc4.xml · derivative · entry 1 Poma Eric E · CIK 0001339484 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,500 Underlying: Common Stock · 312,500 shares Expires 2030-02-14 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 14, 2021, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over 36 months. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 16:31 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $4.66 | $0.00 |
DisclosureSEC source: 0000899243-19-004259 · doc4.xml · derivative · entry 1 Poma Eric E · CIK 0001339484 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-02-15 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 15, 2020, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over 36 months. Read SEC document |
| November 26, 2018 Filed Nov 29, 2018 17:34 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | Exercise / conversionStock Option (right to buy) · Derivative | 86,951 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0000899243-18-029818 · doc4.xml · derivative · entry 4 Poma Eric E · CIK 0001339484 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,563 Underlying: Common Stock · 86,951 shares Expires 2021-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| November 26, 2018 Filed Nov 29, 2018 17:34 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | Exercise / conversionStock Option (right to buy) · Derivative | 152,945 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0000899243-18-029818 · doc4.xml · derivative · entry 3 Poma Eric E · CIK 0001339484 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 152,945 shares Expires 2019-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| November 26, 2018 Filed Nov 29, 2018 17:34 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | Exercise / conversionCommon Stock | 86,951 | $0.71 | $61,735.21 |
DisclosureSEC source: 0000899243-18-029818 · doc4.xml · nonDerivative · entry 2 Poma Eric E · CIK 0001339484 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2018 Filed Nov 29, 2018 17:34 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | Exercise / conversionCommon Stock | 152,945 | $0.42 | $64,236.90 |
DisclosureSEC source: 0000899243-18-029818 · doc4.xml · nonDerivative · entry 1 Poma Eric E · CIK 0001339484 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 16:29 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0000899243-18-014918 · doc4.xml · derivative · entry 1 Poma Eric E · CIK 0001339484 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-05-31 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option shall vest on May 31, 2019, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over 36 months. Read SEC document |
| May 31, 2018 Filed Jul 13, 2018 21:02 UTC Amendment | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 585,126 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0000899243-18-019865 · doc4a.xml · derivative · entry 1 Poma Eric E · CIK 0001339484 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,126 Underlying: Common Stock · 585,126 shares Expires 2028-05-31 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option shall vest on May 31, 2019, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over 36 months. Read SEC document |
| October 09, 2017 Filed Oct 11, 2017 19:13 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $9.40 | $0.00 |
DisclosureSEC source: 0000899243-17-024074 · doc4.xml · derivative · entry 1 Poma Eric E · CIK 0001339484 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2027-10-09 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option shall vest on October 9, 2018, and thereafter, the remaining 75% of the shares subject to the option shall vest pro rata on a monthly basis over 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.